Purine biosynthesis and salvage enzymes

Purine biosynthesis and salvage enzymes are a collection of proteins that maintain the cellular supply of adenine and guanine nucleotides, which are essential for DNA and RNA synthesis, energy transfer, and intracellular signaling [NIH, 1.3.3]. The de novo pathway synthesizes purines from simple precursors like amino acids and carbon dioxide, while the salvage pathway recycles pre-formed bases and nucleosides from the diet or cellular turnover [RSC, 1.2.1]. Because rapidly proliferating cells, such as cancer cells, activated immune cells, and certain pathogens, have an elevated requirement for nucleotides, these enzymes are prominent therapeutic targets [MDPI, 1.2.3]. Antimetabolite drugs like methotrexate and mycophenolate mofetil inhibit key steps in these pathways to treat malignancies, prevent organ transplant rejection, and manage autoimmune conditions [PubMed, 1.4.3]. Additionally, targeting specific enzymes in these pathways, such as xanthine oxidase or purine nucleoside phosphorylase, is a strategy for treating gout and T-cell malignancies [IntechOpen, 1.2.2]. The clinical use of these inhibitors often requires monitoring biomarkers such as thiopurine methyltransferase (TPMT) activity to prevent severe toxicity [AACR, 1.4.1]. Furthermore, the complexity of these pathways often requires consideration of compensatory salvage mechanisms that can lead to drug resistance in oncology [NIH, 1.3.4].

Other names

Purine metabolic enzymesPurine nucleotide synthesis pathway enzymesPurine biosynthesis and salvage pathwayPurine metabolism enzymes

Inhibition of specific enzymes within the de novo or salvage pathways to deplete cellular purine nucleotide pools (ATP and GTP), thereby inhibiting DNA and RNA synthesis, arresting the cell cycle, and inducing apoptosis in rapidly dividing cells [PubMed, 1.4.3; RSC, 1.2.1].